Iovance Biotherapeutics is trading at $11.05, down 25.39%, after updated Phase 2 lung-cancer results showed a 24.6% response rate in 69 patients, consistent with previously reported results.
- Reports linked the selloff to investors reassessing webcast details after an after-hours rally, while the broader market was also weaker.
- A biomarker-defined subgroup had a 59.1% response rate; the company plans to begin enrolling a specialized study arm in November.